Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.

By T. Yousry, E. Major, C. Ryschkewitsch, G. Fahle, S. Fischer, J. Hou, B. Curfman, K. Miszkiel, N. Mueller-Lenke, E. Sánchez and 4 more. New England Journal of Medicine, 2006

811 citations recorded by the source corpus.

Subfields: Ecology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/c27b703adefb2d4e76cd175236ed5760caeeac84

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Subramanyam
2. A. George
3. T. Singer
4. J. Mitchell
5. A. Sandrock
6. H. Kropshofer
7. J. Scanlon
8. A. Natarajan

Citations in the corpus

• The safety and side effects of monoclonal antibodies (2010, background): “Based on a detailed review of 3,147 patients taking part in clinical trials with natalizumab, it has been estimated that the risk of PML corresponds to about 1 in 1,000 patients treated, occurring after a mean of about 18 months of natalizumab treatmen”
• Risk of natalizumab-associated progressive multifocal leukoencephalopathy. (2012, background): “Data on the incidence of PML in clinical trials are from Yousry and colleagues.(7) Estimates of the incidence of PML in the postmarketing setting were based on natalizumab exposure and the 212 confirmed cases of PML as of February 29, 2012.”